ASCO News In Brief: Coulter Pharmaceuticals 131-I-anti-B1
Coulter Pharmaceuticals 131-I-anti-B1: Anti-CD20 monoclonal antibody non-myeloablative radioimmunotherapy shows 72% complete or partial remission rate in B-cell lymphoma patients who failed prior chemotherapy, Mark Kaminiski, MD, University of Michigan Medical Center, reports. The 47-patient Phase I/II study treated patients with an initial tracer dose of 131-I-anti-B1 (15-20 mg with 5 mCi) for a one week evaluation and then a therapeutic dose of 685 mg unlabeled anti-B1 prior to optimize targeting of the radioactive antibody. Patient received radioimmunotherapy from 25 to 85 cGy. The median complete remission response was 16 months with a range of four to 38 months. Non-hematologic side effects in the study were minimal and myelosuppression was the dose-limiting toxicity. A mid-1997 NDA filing is planned...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth